Additionally, the combination of anti-CD73, anti-TNFRSF4, and mCTH-ANXA5 mAbs can be used to significantly improve the survival rate (12–24 days for all murine objects) and to reduce the burden of metastatic ovarian cancer by enhancing the function of cytotoxic T cells (129). This evidence concerns the gene TNFRSF4 and ovarian cancer.